MPO and COVID-19: A first, analysis in all COVID-19 patients showed no difference in plasma levels of NET markers (total DNA, MPO—DNA, and H3Cit, respectively; Figures 1D–F) between patients treated with prophylactic or therapeutic anticoagulant treatment.